Implications of vancomycin degradation products on therapeutic drug monitoring in patients with end-stage renal disease

Pharmacotherapy

Volumn 19, Issue 6, 1999, Pages 702-707

  Somerville, Allison L ^a   Wright, David H ^a,b   Rotschafer, John C ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b REGIONS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; UNCLASSIFIED DRUG; VANCOMYCIN; VANCOMYCIN CRYSTALLINE DEGRADATION PRODUCT;

DRUG ACCUMULATION; DRUG DETERMINATION; DRUG HALF LIFE; DRUG MONITORING; DRUG STRUCTURE; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FLUORESCENCE POLARIZATION; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FAILURE; RADIOIMMUNOASSAY; REVIEW;

ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRYSTALLIZATION; DRUG MONITORING; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMANS; KIDNEY FAILURE, CHRONIC; RADIOIMMUNOASSAY; REFERENCE STANDARDS; VANCOMYCIN;

EID: 0033031933     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.9.702.31548     Document Type: Review

References (28)

1. Griffith RS. Vancomycin use - an historical review. J Antimicrob Chemother 1984;14(suppl D):1-5.
2. Rotschafer JC, Crossley K, Zaske DE, Mead K, Sawchuck RJ, Solem LD. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother 1982;22(3):391-4.
3. Morse GD, Nairn DK, Bertino JS, Walshe JJ. Overestimation of vancomycin concentrations utilizing fluorescence polarization immunoassay in patients on peritoneal dialysis. Ther Drug Monit 1987;9:212-15,
4. Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of vancomycin. Antimicrob Agents Chemother 1998;42(5):1303-4.
5. Pryka RD, Rodvold KA, Erdman SM. An updated comparison of drug dosing methods. IV. Vancomycin. Clin Pharmacokinet 1991;20(6):463-76.
6. Cantu TG, Yamanaka-Yeun NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994;18:533-43.
7. Moellering RC. Monitoring serum vancomycin levels: climbing the mountain because it is there? [editorial] Clin Infect Dis 1994;18:544-6.
8. White IO, Edwards R, Holt HA, Lovering AM, Finch RG, Reeves DS. The in-vitro degradation at 37C of vancomycin in serum, CAPD fluid and phosphate-buffered saline. J Antimicrob Chemother 1988;22:739-45.
9. Yeo K-T, Traverse W, Horowitz GL. Clinical performance of the EMIT vancomycin assay. Clin Chem 1989;35(7):1504-7.
10. Anne L, Hu M, Chan K, Colin L, Gottwald K. Potential problem with fluorescence polarization immunoassay cross-reactivity to vancomycin degradation product CDP-1: its detection in sera of renally impaired patients. Ther Drug Monit 1989;11:585-91.
11. 12 internal standard: comparison of high-performance liquid chromatography, EMIT, and fluorescence polarization immunoassay methods. Ther Drug Monit 1990;12:562-9.
12. Hortin GL, Landt M, Wilhite T, Smith CH. Cross-reactivity of a vancomycin degradation product in three immunoassays of vancomycin. Clin Chem 1991;37(11):2009.
13. Follin SL, Mueller BA, Scott MK, Carfagna MA, Kraus MA. Falsely elevated serum vancomycin concentrations in hemodialysis patients. Am J Kidney Dis 1996;27(1):67-74.
14. Morishige H, Shuto H, Ieiri I, Otsubo K, Oishi R. Instability of standard calibrators may be involved in overestimating vancomycin concentrations determined by fluorescence polarization immunoassay. Ther Drug Monit 1996;18:80-5.
15. Harris CM, Kopecka H, Harris TM. Vancomycin: structure and transformation to CDP-1. J Am Chem Soc 1983;105: 6915-22.
16. Marshall FJ. Structure studies on vancomycin. J Med Chem 1965;39(8):18-22.
17. Moellering RC, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981;94:343-6.
18. Hammett-Stabler CA, Johns T. Laboratory guidelines for monitoring of antimicrobial drugs. Clin Chem 1998;44(5): 1129-40.
19. Waller MA, Krogstad DJ, Granich GG, Murray PR. Laboratory evaluation of five assay methods for vancomycin: bioassay, high-pressure liquid chromatography, fluorescence polarization immunoassay, radioimmunoassay, and fluorescence immunoassay. J Clin Microbiol 1984;20(3): 311-16.
20. Smith PF, Petros WP, Soucie MP, Copeland KR. Falsely elevated vancomycin concentrations in endstage renal disease: lack of cross-reactivity with a modified FPIA assay [abstr]. Presented at the annual meeting of the American College of Clinical Pharmacy, Phoenix, AZ, November 9-12, 1997
21. Smith PF, Petros WP, Soucie MP, Copeland KR. New modified fluorescence polarization immunoassay does not falsely elevate vancomycin concentrations in patients with end-stage renal disease. Ther Drug Monit 1998;20(2):231-5.
22. Geraci JE, Heilman FR, Nichols DR, Wellman WE. Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis. Proc Staff Meet Mayo Clin 1958;33:172-81.
23. Saunders NJ. Vancomycin administration and monitoring reappraisal. J Antimicrob Chemother 1995;36:279-82.
24. Rodvold KA, Zokufa H, Rotschafer JC. Routine monitoring of serum vancomycin concentrations: can waiting be justified? Clin Pharm 1987;6:655-8.
25. Flandrois JP, Fardel G, Carret G. Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus. Antimicrob Agents Chemother 1988;32:454-7.
26. Peetermans WE, Hoogeterp JJ, Hazerkamp-van Dokkum AM, van den Broek P, Mattie H. Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection. Antimicrob Agents Chemother 1990;34:455-61.
27. Ackerman BH, Vannier AM, Eudy EB. Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve-stripping program to describe the relationship between concentration and pharmacodynamic response. Antimicrob Agents Chemother 1992;36:1766-9.
28. Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988;32(6):848-52.